Knowledge

In January 2026, UBC Okanagan researchers advanced a “passive” tremor-reducing brace, a non-electronic device using mechanical principles to absorb and dissipate kinetic energy from hand tremors. This innovation offers a battery-free, maintenance-light alternative to active neurostimulation devices, potentially improving accessibility and daily usability for patients with essential tremor or Parkinson’s disease. Medical Equipment Store | […]

The global essential tremor treatment market, valued at $210 million in March 2026, is a dynamic sector driven by the increasing adoption of non-invasive wearable technology and a growing demand for effective, patient-centric solutions. This growth, projected at a 5.1% CAGR, reflects a shift from traditional pharmaceuticals to advanced neuromodulation devices, creating a complex landscape

In early 2026, Cala Health’s strategic partnership with major Parkinson’s disease (PD) foundations marked a pivotal shift, integrating its kIQ wearable therapy into standard “Day 1” treatment plans. This move, driven by advocacy and clinical evidence, positions non-invasive neuromodulation as a foundational tool for tremor management alongside traditional medications. The initiative aims to improve patient

Supply Chain Resilience: Cala’s “Direct-to-Clinic” Model represents a strategic pivot in medical device distribution, focusing on bypassing traditional multi-tiered channels to deliver essential tremor therapy devices like the kIQ directly to healthcare providers. This model, highlighted in a 2026 logistics report, is a proactive response to global supply chain volatility, ensuring consistent patient access through

In mid-2026, Cala Therapeutics announced its pursuit of the CE Mark and Japanese PMDA approval for its kIQ Plus wearable therapy for essential tremor. This strategic global expansion into the EU and Asian markets represents a significant shift, aiming to bring the non-invasive neuromodulation device to millions of new patients. For medical equipment traders and

In February 2026, major North American health networks fully integrated Cala kIQ neuromodulation devices into cloud-based clinic procurement systems. This enables just-in-time (JIT) inventory management, allowing clinics to order wearables automatically as needed, cutting storage costs and ensuring patient access to tremor therapy. HHG GROUP highlights this as a supply chain game-changer. Medical Equipment Store

AI‑driven procurement software for healthcare providers is transforming how hospitals and clinics source medical technology, including advanced devices like the Cala kIQ system. Using predictive analytics, new platforms launched in Q1 2026 forecast when patients with Essential Tremor are most likely to need device upgrades, aligning purchases with clinical demand. This shift turns the Cala

Tracking hospital equipment utilization for neuromodulation devices such as Cala kIQ units improves ROI by identifying real usage patterns, reducing idle time, and supporting data-driven purchasing decisions. Clinics achieving up to 95% daily utilization can justify fleet expansion, optimize patient access, and lower operational costs while maximizing revenue from each device across the care continuum.

Cala Health’s expansion of OEM services is transforming neurotechnology by enabling companies to license its TAPS architecture for customized device development. This approach reduces development time, lowers costs, and promotes standardization across medical hardware. As adoption grows, it could enhance innovation, improve patient access to advanced therapies, and strengthen compatibility across the global healthcare ecosystem.

Yes, on April 16, 2026, the U.S. Food and Drug Administration granted 510(k) clearance for the Cala kIQ Plus, an updated wrist‑worn neurostimulation system for on‑demand tremor relief in Essential Tremor and Parkinson’s Disease. The device builds on TAPS Therapy with adaptive calibration and new therapy modes, offering greater precision, comfort, and clinical utility than